Synlogic, Inc. (SYBX)
Largest Insider Buys in Sector
SYBX Stock Price History Chart
SYBX Stock Performance
About Synlogic, Inc.
Synlogic, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotic medicines to treat metabolic and immunological diseases in the United States. Its therapeutic programs include SYNB1618 and SYNB1934 that are orally administered, non-systemically absorbed drug candidates, which are in Phase II clinical trials to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate to treat homocystinuria; and SYNB8802, an orally administered, non-systemically absorbed drug candidate that is in Phase I clinical trial for the treatment of enteric hyperoxaluria. The company is also developing SYNB1891, an intratumorally administered synthetic biotic medicine that is in Phase I clinical trial to treat solid tumors and lymphoma. It has a collaboration agreement with F. Hoffmann-La Roche Ltd; Hoffmann-La Roche Inc.; and Ginkgo Bioworks, Inc. Synlogic, Inc. is headquartered in Cambridge, Massachusetts.
Insider Activity of Synlogic, Inc.
Over the last 12 months, insiders at Synlogic, Inc. have bought $0 and sold $969 worth of Synlogic, Inc. stock.
On average, over the past 5 years, insiders at Synlogic, Inc. have bought $15,595 and sold $15,115 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 9,500 shares for transaction amount of $10,640 was made by JENSEN MICHAEL VANGSTED (Chief Financial Officer) on 2022‑05‑24.
List of Insider Buy and Sell Transactions, Synlogic, Inc.
| 2024-04-02 | Sale | Awad Antoine | Chief Operating Officer | 372 0.0031% | $1.73 | $644 | -0.85% | |
| 2024-04-02 | Sale | Dooley Mary Beth | Head of Finance | 188 0.0016% | $1.73 | $325 | -0.85% | |
| 2023-04-03 | Sale | Brennan Aoife | See Remarks | 19,042 0.0274% | $0.58 | $10,964 | +200.86% | |
| 2023-04-03 | Sale | Awad Antoine | Chief Operating Officer | 6,438 0.0093% | $0.58 | $3,707 | +200.86% | |
| 2023-04-03 | Sale | JENSEN MICHAEL VANGSTED | Chief Financial Officer | 2,553 0.0037% | $0.58 | $1,470 | +200.86% | |
| 2022-05-24 | JENSEN MICHAEL VANGSTED | Chief Financial Officer | 9,500 0.0132% | $1.12 | $10,640 | -20.36% | ||
| 2022-04-04 | Sale | Brennan Aoife | See Remarks | 8,894 0.0129% | $2.45 | $21,754 | -57.73% | |
| 2022-04-04 | Sale | Awad Antoine | Chief Operating Officer | 2,650 0.0039% | $2.45 | $6,482 | -57.73% | |
| 2019-12-13 | Shea Richard P | director | 7,500 0.0252% | $2.74 | $20,550 | -7.98% | ||
| 2019-02-13 | Sale | Miller Paul Francis | Chief Scientific Officer | 5,849 0.022% | $9.75 | $57,028 | -53.61% | |
| 2019-02-12 | Sale | Miller Paul Francis | Chief Scientific Officer | 3,151 0.0127% | $9.75 | $30,722 | -50.05% | |
| 2018-10-18 | Sale | Miller Paul Francis | Chief Scientific Officer | 3,000 0.0132% | $9.77 | $29,296 | -16.09% | |
| 2018-09-18 | Sale | Miller Paul Francis | Chief Scientific Officer | 3,000 0.0119% | $13.05 | $39,163 | -38.59% | |
| 2018-09-05 | Sale | Miller Paul Francis | Chief Scientific Officer | 3,000 0.0117% | $12.55 | $37,635 | -36.76% | |
| 2018-08-30 | Sale | Miller Paul Francis | Chief Scientific Officer | 1,342 0.0052% | $9.76 | $13,092 | -19.08% | |
| 2018-08-29 | Sale | Miller Paul Francis | Chief Scientific Officer | 1,658 0.0067% | $9.77 | $16,198 | -15.54% | |
| 2018-07-18 | Sale | Miller Paul Francis | Chief Scientific Officer | 3,000 0.0118% | $11.01 | $33,022 | -25.32% | |
| 2018-06-20 | Sale | Miller Paul Francis | Chief Scientific Officer | 2,054 0.0081% | $9.78 | $20,079 | -17.00% | |
| 2018-06-19 | Sale | Miller Paul Francis | Chief Scientific Officer | 946 0.0039% | $9.75 | $9,224 | -13.81% | |
| 2016-12-01 | Sale | Irvin Jon | Vice President, Finance | 280 0.0013% | $1.43 | $402 | +30.95% |
Insider Historical Profitability
| Awad Antoine | Chief Operating Officer | 33859 0.8132% | $1.52 | 0 | 3 | |
| Dooley Mary Beth | Head of Finance | 15231 0.1308% | $1.52 | 0 | 1 | |
| POWELL MICHAEL | 2974811 32.3724% | $1.52 | 1 | 0 | <0.0001% | |
| Sofinnova Venture Partners VIII, L.P. | 10 percent owner | 2974811 32.3724% | $1.52 | 1 | 0 | <0.0001% |
| MOTT DAVID M | 10 percent owner | 2971517 32.3365% | $1.52 | 1 | 0 | <0.0001% |
| BARRIS PETER J | 10 percent owner | 2971517 32.3365% | $1.52 | 1 | 0 | <0.0001% |
| BASKETT FOREST | 10 percent owner | 2971517 32.3365% | $1.52 | 1 | 0 | <0.0001% |
| Weller Harry R | 10 percent owner | 2971517 32.3365% | $1.52 | 1 | 0 | <0.0001% |
| BARRETT M JAMES | 10 percent owner | 2971517 32.3365% | $1.52 | 1 | 0 | <0.0001% |
| SANDELL SCOTT D | 10 percent owner | 2971517 32.3365% | $1.52 | 1 | 0 | <0.0001% |
| KERINS PATRICK J | 10 percent owner | 2971517 32.3365% | $1.52 | 1 | 0 | <0.0001% |
| Sonsini Peter W. | 10 percent owner | 2971517 32.3365% | $1.52 | 1 | 0 | <0.0001% |
| Viswanathan Ravi | 10 percent owner | 2971517 32.3365% | $1.52 | 1 | 0 | <0.0001% |
| KOLLURI KRISHNA KITTU | 10 percent owner | 2971517 32.3365% | $1.52 | 1 | 0 | <0.0001% |
| Florence Anthony A. Jr. | 10 percent owner | 2971517 32.3365% | $1.52 | 1 | 0 | <0.0001% |
| New Enterprise Associates 14, L.P. | 10 percent owner | 2971517 32.3365% | $1.52 | 1 | 0 | <0.0001% |
| PFIZER INC | 10 percent owner | 2253509 24.5231% | $1.52 | 1 | 0 | <0.0001% |
| Brennan Aoife | See Remarks | 256301 2.7891% | $1.52 | 0 | 2 | |
| Miller Paul Francis | Chief Scientific Officer | 48135 0.5238% | $1.52 | 0 | 10 | |
| JENSEN MICHAEL VANGSTED | Chief Financial Officer | 46947 0.5109% | $1.52 | 1 | 1 | <0.0001% |
| Irvin Jon | Vice President, Finance | 7625 0.083% | $1.52 | 0 | 5 | |
| Shea Richard P | director | 7500 0.0816% | $1.52 | 1 | 0 | <0.0001% |
Institutional Investor Ownership
No records found… | |||||||